Just dont overdo it, as too much caffeine can dehydrate you further if youre not careful
S., Mora, S., Gibson, H., Albert, C
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase
Each method has its own rules and when to use it
Unapproved ingredients are deemed impermissible for inclusion in supplements by a regulatory body, like the Food and Drug Administration (FDA), with a common example being active pharmaceutical ingredients
